- Home
- EDF vs SCPH Comparison
EDF vs SCPH Comparison
Compare EDF & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- SCPH
- Stock Information
- Founded
- EDF 2010
- SCPH 2013
- Country
- EDF United States
- SCPH United States
- Employees
- EDF N/A
- SCPH N/A
- Industry
- EDF Investment Managers
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- SCPH Health Care
- Exchange
- EDF Nasdaq
- SCPH Nasdaq
- Market Cap
- EDF 148.8M
- SCPH 173.6M
- IPO Year
- EDF N/A
- SCPH 2017
- Fundamental
- Price
- EDF $5.06
- SCPH $3.81
- Analyst Decision
- EDF
- SCPH Strong Buy
- Analyst Count
- EDF 0
- SCPH 3
- Target Price
- EDF N/A
- SCPH $14.00
- AVG Volume (30 Days)
- EDF 160.6K
- SCPH 301.8K
- Earning Date
- EDF 01-01-0001
- SCPH 08-13-2025
- Dividend Yield
- EDF 13.14%
- SCPH N/A
- EPS Growth
- EDF N/A
- SCPH N/A
- EPS
- EDF N/A
- SCPH N/A
- Revenue
- EDF N/A
- SCPH $41,982,000.00
- Revenue This Year
- EDF N/A
- SCPH $108.95
- Revenue Next Year
- EDF N/A
- SCPH $73.83
- P/E Ratio
- EDF N/A
- SCPH N/A
- Revenue Growth
- EDF N/A
- SCPH 138.10
- 52 Week Low
- EDF $3.51
- SCPH $1.94
- 52 Week High
- EDF $5.50
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- EDF 60.99
- SCPH 61.62
- Support Level
- EDF $4.96
- SCPH $3.84
- Resistance Level
- EDF $5.07
- SCPH $4.03
- Average True Range (ATR)
- EDF 0.06
- SCPH 0.18
- MACD
- EDF -0.00
- SCPH -0.05
- Stochastic Oscillator
- EDF 76.47
- SCPH 40.58
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.